CTS™ KnockOut™ SR XenoFree Medium
CTS™ KnockOut™ SR XenoFree Medium
Zitierungen und Referenzen (5)
Gibco™

CTS™ KnockOut™ SR XenoFree Medium

Gibco CTS KnockOut SR XenoFree Medium, als vollständiges Medium formuliert, ermöglicht das Wachstum und die Expansion humaner embryonaler Stammzellen (hESC)Weitere Informationen
Have Questions?
Ansicht ändernbuttonViewtableView
KatalognummerMenge
12618013500 mL
12618012100 mL
Katalognummer 12618013
Preis (EUR)
760,00
Each
Zum Warenkorb hinzufügen
Menge:
500 mL
Preis (EUR)
760,00
Each
Zum Warenkorb hinzufügen
Gibco CTS KnockOut SR XenoFree Medium, als vollständiges Medium formuliert, ermöglicht das Wachstum und die Expansion humaner embryonaler Stammzellen (hESC) und humaninduzierter pluripotenter Stammzellen (hiPSC) in einem Zellkulturmedium, das nur humane oder rekombinante humane Proteine enthält, um den Übergang der hESC- und hiPSC-Forschung vom Labor in die Klinik zu erleichtern.

Die CTS Produktlinie bedeutet eine erhebliche Arbeitserleichterung für die Eignungsprüfung von Reagenzien bei der Übertragung von Forschungsanwendungen auf klinische Anwendungen.

Das CTS KnockOut SR XenoFree Medium enthält keine bovinen oder andere nicht-menschliche, tierische Bestandteile. Neben der Expansion und Erhaltung pluripotenter Stammzellkulturen kann CTS KnockOut SR XenoFree Medium für Kryokonservierungs-, Herkunfts- und Differenzierungsstudien mit hESC⁄hiPSC verwendet werden.

GIBCO CTS Produkte sind von hoher Qualität und werden mit harmonisierter Dokumentation geliefert, wie z. B. Analysenzertifikate, Herkunftszertifikate und Zugriff auf Genehmigungsschreiben für unsere Drug Master Files – je nach Bedarf.
Für die Verwendung in der Forschung oder die Herstellung von zell-, gen- oder gewebebasierten Produkten. ACHTUNG: Nicht für Anwendungen an Menschen oder Tieren geeignet.
Specifications
ZelltypEmbryonale Stammzellen (ESCs), induzierte pluripotente Stammzellen (iPSCs)
Zur Verwendung mit (Anwendung)Zelltherapie, klinische Forschung, translationale Forschung
FormatFlasche
Fertigungsqualität, HerstellungsqualitätcGMP für Medizinprodukte, 21 CFR Part 820 und ISO 13485
ProdukttypStammzellmedien
Menge500 mL
VersandbedingungTrockeneis
KlassifikationSerumfrei
FormFlüssig
Serum LevelSerumfrei
SterilitätSteril gefiltert
Unit SizeEach
Inhalt und Lagerung
Bei -5 bis -20 °C lagern und vor Licht schützen

Häufig gestellte Fragen (FAQ)

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Do you offer a medical device–grade of CTS KnockOut SR XenoFree Medium?

Yes, we do offer a Class II medical device–labeled CTS KnockOut SR XenoFree Medium in the USA and Canada only. Please contact us at custommedia@thermofisher.com to discuss if a medical device grade is required for your application.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

How do I characterize human embryonic stem ( ES) cells?

Human ES cells are generally characterized by their typical morphology (they grow as tightly packed clusters of small cells with high ratio of nucleus to cytoplasm); surface marker expression; RT-PCR detection of stem cell-specific gene expression (such as Oct3/4, Sox2, and Nanog); alkaline phosphatase staining, and telomerase activity assay. The most commonly used ES specific surface markers include stage-specific embryonic antigens SSEA-3 and SSEA-4 for human ES cells. Other ES-specific surface antigens also include TRA-1-60 and TRA-1-81. (Science 282:1145 (1998).

How are human embryonic stem (ES) cells derived?

Human ES cells are derived from human blastocyst inner cell masses, isolated by immunosurgery with rabbit antiserum to BeWO cells (a human trophoblast cell line) (Science 282:1145 (1998)).

What are ES cells?

Embryonic stem (ES) cells are derived from the early mammalian embryo and are capable of unlimited, undifferentiated proliferation in vitro while maintaining their potential to differentiate into a wide of range of adult tissues including germ cells. The pluripotency of the ES cells is normally demonstrated in vitro by inducing ES cells to differentiate into embryoid bodies and checking lineage-specific markers for differentiated cells in three body layers (endo, meso, and ectoderm), or injecting them into immunodeficient mice and determining the cell types produced in the teratomas.

Zitierungen und Referenzen (5)

Zitierungen und Referenzen
Abstract
CD133-enriched Xeno-Free human embryonic-derived neural stem cells expand rapidly in culture and do not form teratomas in immunodeficient mice.
Authors:Haus DL, Nguyen HX, Gold EM, Kamei N, Perez H, Moore HD, Anderson AJ, Cummings BJ
Journal:
PubMed ID:25082219
'Common methods for the generation of human embryonic-derived neural stem cells (hNSCs) result in cells with potentially compromised safety profiles due to maintenance of cells in conditions containing non-human proteins (e.g. in bovine serum or on mouse fibroblast feeders). Additionally, sufficient expansion of resulting hNSCs for scaling out or up ... More
An ECM-based culture system for the generation and maintenance of xeno-free human iPS cells.
Authors:Kim HT, Lee KI, Kim DW, Hwang DY
Journal:Biomaterials
PubMed ID:23153417
'Pluripotent stem cells (PSCs) including induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) have emerged as a promising source for treating incurable diseases. Problems that urgently need to be resolved before the clinical application include avoiding potential xenopathogenic transmission and immune rejection that may be caused by the ... More
Concise Review: Manufacturing of Pancreatic Endoderm Cells for Clinical Trials in Type 1 Diabetes.
Authors:Schulz TC,
Journal:
PubMed ID:26062982
'The cellular component of ViaCyte''s VC-01 combination product for type 1 diabetes, pancreatic endoderm cells (PEC-01) derived from CyT49 human embryonic stem cells, matures after transplantation and functions to regulate blood glucose in rodent models. The aims in manufacturing PEC-01 at scale are to generate a consistent and robust transplantable ... More
Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions.
Authors:Macarthur CC, Fontes A, Ravinder N, Kuninger D, Kaur J, Bailey M, Taliana A, Vemuri MC, Lieu PT,
Journal:Stem Cells Int
PubMed ID:22550511
The generation of induced pluripotent stem cells (iPSCs) from somatic cells has enabled the possibility of providing unprecedented access to patient-specific iPSC cells for drug screening, disease modeling, and cell therapy applications. However, a major obstacle to the use of iPSC for therapeutic applications is the potential of genomic modifications ... More
cGMP production of patient-specific iPSCs and photoreceptor precursor cells to treat retinal degenerative blindness.
Authors:Wiley LA, Burnight ER, DeLuca AP, Anfinson KR, Cranston CM, Kaalberg EE, Penticoff JA, Affatigato LM, Mullins RF, Stone EM, Tucker BA,
Journal:Sci Rep
PubMed ID:27471043
'Immunologically-matched, induced pluripotent stem cell (iPSC)-derived photoreceptor precursor cells have the potential to restore vision to patients with retinal degenerative diseases like retinitis pigmentosa. The purpose of this study was to develop clinically-compatible methods for manufacturing photoreceptor precursor cells from adult skin in a non-profit cGMP environment. Biopsies were obtained ... More